Go To App
Go To App

Canada Updates Medical Devices Regulations for Recalls and Post-Market Surveillance

Canada has strengthened oversight of medical devices through updated recall procedures, establishment licensing, and post-market surveillance requirements.

CANADA – MEDICAL DEVICES

Canada Tightens Medical Device Safety Rules

Manufacturers must test products, hold licenses, and monitor performance after sale.

What changed

Establishment licensing required for all manufacturers and distributors before operations begin.

Finished product testing mandated to verify safety and performance standards prior to market release.

Post-market surveillance strengthened with mandatory monitoring and reporting of adverse events.

Time-bound recall procedures mandated for defective or unsafe devices to ensure timely removal.

Who it affects

Manufacturers must obtain licenses, conduct testing, and report adverse events for devices like pacemakers.

Distributors are now subject to new establishment licensing requirements.

Canada — medical device safety and oversight

Regulation Analysis: Strengthened Oversight of Medical Devices in Canada

Canada has enhanced its regulatory framework for medical devices through recent amendments to the Medical Devices Regulations (MDR) and Food and Drug Regulations (FDR), focusing on recall procedures, establishment licensing, and post-market surveillance. The key changes are outlined below, with their respective requirements, deadlines, and authorities.

Key Amendments and Requirements

  1. Recall Procedures
    • The amendments clarify industry obligations for conducting recalls of therapeutic products, including medical devices, to align with international best practices1.
    • Voluntary recall requirements in the MDR are updated to improve consistency with foreign regulatory authorities1.
  1. Establishment Licensing
    • Modernized application requirements for establishment licences under the MDR, enabling Health Canada to impose terms and conditions on licences for targeted compliance and enforcement actions1.
    • These changes allow for more flexible and risk-based oversight of medical device establishments1.
  1. Post-Market Surveillance
    • While the provided sources do not explicitly detail new post-market surveillance requirements, the amendments emphasize risk-based measures to strengthen oversight of medical devices throughout their lifecycle1.
  1. Foreign Regulatory Authorities
    • The outdated list of foreign regulatory authorities in Section C.01A.019 of the FDR has been replaced to reflect current international partnerships1.
    • The updated list is available on Health Canada’s website1.
  1. Finished Product Testing Exemptions
    • Conditional exemptions from certain finished product testing requirements are introduced for novel and complex biologics and radiopharmaceuticals under the FDR1.
    • These exemptions apply only under specific conditions and are intended to reduce redundant testing while maintaining safety1.

Compliance Timeline

RegulationKey RequirementDeadlineAuthority
Food and Drug Regulations (FDR)Updated list of foreign regulatory authorities for Section C.01A.0191.June 17, 2024Health Canada
FDRConditional exemptions for finished product testing of biologics/radiopharmaceuticals1.June 17, 2024Health Canada
FDRClarified recall obligations for therapeutic products1.December 14, 2024Health Canada
Medical Devices Regulations (MDR)Modernized establishment licence requirements and terms/conditions1.December 14, 2024Health Canada
MDRUpdated voluntary recall requirements for international alignment1.December 14, 2024Health Canada

Supporting Guidance

  • Annex 2 to the Good Manufacturing Practices Guide (GUI-0027) provides updated requirements for the manufacture of biologics, including direct shipment and finished product testing1.
  • Annex 3A to the Good Manufacturing Practices Guide (GUI-0026) outlines changes related to the direct shipment of radiopharmaceuticals1.

Summary Answer

Canada’s strengthened oversight of medical devices is implemented through amendments to the Medical Devices Regulations (MDR) and Food and Drug Regulations (FDR), effective in two phases: June 17, 2024 (foreign regulatory authorities and finished product testing exemptions) and December 14, 2024 (recall procedures and establishment licensing updates)1. Key changes include clarified recall obligations, modernized establishment licence requirements, and conditional exemptions for biologics/radiopharmaceuticals1. These measures align with international best practices and introduce risk-based tools for more agile regulatory oversight1. For detailed guidance, refer to Health Canada’s updated Good Manufacturing Practices Guides (GUI-0026 and GUI-0027)1.

Sources

  1. ↩ Regulations Amending the Food and Drug Regulations and the Medical Devices Regulations (Recalls, Establishment Licences and Finished Product Testing) https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=q:/G/TBTN23/CAN694A1.pdf&Open=True
Back to Blog Overview
Next Post

Create your account